Previous 10 | Next 10 |
Leading experts in neuroscience will provide guidance to support the advancement of Aptinyx’s novel NMDA receptor modulation platform and pipeline Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treat...
Catalyst-rich year with data readouts expected from three Phase 2 studies across chronic pain and cognitive impairment development programs Advancing PTSD development program with initiation of Phase 2b studies Strong balance sheet expected to fund Phase 2 readouts fro...
Event will review the company’s pipeline of clinical development programs, with a deep dive on NYX-2925 and chronic pain Featured presentation by Dr. Richard Rauck, board certified physician in pain medicine and anesthesiology at Carolinas Pain Institute and medical...
Aptinyx (NASDAQ:APTX) has initiated a Phase 2b study evaluating 50 mg QD of NYX-783 in 300 patients with post-traumatic stress disorder (PTSD). Shares up 2.9% premarket at $2.80. The company anticipates reporting data from the Phase 2b study in H2 2023. The NYX-783 Phase 2b PTSD pro...
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the initiation of a Phase 2b study evaluating 50 mg QD of NYX-783 in 300 patients with post-traumatic stre...
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will present at the 40 th Annual J.P. M...
A series of insider purchases have propelled microcap biotech Aptinyx (NASDAQ:APTX) higher. The latest to purchase company shares was Aptinyx (APTX) CEO, Norbert G. Riedel. In a transaction dated Dec. 06, Riedel has bought 100K shares, the company disclosed in a regulatory filing on Wedn...
Aptinyx (APTX +6.7%) shares have surged after Ashish Khanna, Chief Financial Officer (CFO) and Chief Business Officer (CBO), purchased 45,000 company shares, worth ~$100K. The shares were bought at $2.18 - $2.32 in a transaction dated Dec. 02, 2021. Form 4 A look at Aptinyx's ownership compos...
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in a fireside chat at the Piper Sandler 33 rd Annual Virtual ...
Kezar Life Sciences (NASDAQ:KZR) +46% on phase 2 data for lupus candidate Axon Enterprise (NASDAQ:AXON) +24% on Q3 results Cyclo Therapeutics (NASDAQ:CYTH) +19% on Q3 results. Comstock Holding Companies (NASDAQ:CHCI) +20% on Q3 results. Romeo Power (NYS...
News, Short Squeeze, Breakout and More Instantly...
Signature Bank (SBNY) is expected to report for Q3 2023 BHP Group Ltd. (BHP) is expected to report for Q1 2024 Sorrento Therapeutics Inc. (SRNEQ) is expected to report $-0.15 for Q3 2023 Baran Group Ltd. (BRANF) is expected to report for quarter end 2023-09-30 World Copper (WCUFF)...
GLG Life Tech Corporation (GLGLF) is expected to report for Q1 2024 Accenture plc Class A (Ireland) (ACN) is expected to report $3.14 for Q1 2024 Greenlane Holdings Inc. (GNLN) is expected to report $-2.7 for Q3 2023 iMedia Brands Inc. (IMBIQ) is expected to report for quarter end 202...
Axcella Health Inc. (AXLA) is expected to report for Q3 2023 Telekom Malaysia Bhd (MYTEF) is expected to report for quarter end 2023-09-30 Atento S.A. (ATTOF) is expected to report for Q3 2023 Scryb Inc Com (SCYRF) is expected to report for Q4 2023 BHP Group Ltd. (BHP) is expected...